Viking Therapeutics (NASDAQ:VKTX) was upgraded by ValuEngine from a “buy” rating to a “strong-buy” rating in a research note issued on Thursday.

A number of other equities analysts have also weighed in on the company. BidaskClub upgraded Viking Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, February 7th. Maxim Group reiterated a “buy” rating and issued a $8.00 price target on shares of Viking Therapeutics in a research report on Friday, February 2nd. HC Wainwright reiterated a “buy” rating and issued a $11.00 price target on shares of Viking Therapeutics in a research report on Monday, March 26th. William Blair initiated coverage on Viking Therapeutics in a research report on Monday, April 30th. They issued an “outperform” rating for the company. Finally, Roth Capital set a $8.00 price target on Viking Therapeutics and gave the company a “buy” rating in a research report on Thursday, March 8th. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $9.00.

Viking Therapeutics opened at $5.13 on Thursday, Marketbeat.com reports. Viking Therapeutics has a 1-year low of $4.58 and a 1-year high of $4.98. The firm has a market capitalization of $234.80 million, a P/E ratio of -6.49 and a beta of 2.10.

Viking Therapeutics (NASDAQ:VKTX) last released its quarterly earnings results on Wednesday, May 9th. The biotechnology company reported ($0.10) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.12) by $0.02. research analysts expect that Viking Therapeutics will post -0.45 earnings per share for the current fiscal year.

A number of institutional investors have recently made changes to their positions in VKTX. Sphera Funds Management LTD. lifted its stake in Viking Therapeutics by 639.8% in the 4th quarter. Sphera Funds Management LTD. now owns 2,145,300 shares of the biotechnology company’s stock worth $8,710,000 after acquiring an additional 1,855,300 shares in the last quarter. Millennium Management LLC purchased a new stake in Viking Therapeutics in the 4th quarter worth about $2,854,000. EAM Investors LLC purchased a new stake in Viking Therapeutics in the 4th quarter worth about $2,538,000. Opaleye Management Inc. lifted its stake in Viking Therapeutics by 129.1% in the 1st quarter. Opaleye Management Inc. now owns 1,100,800 shares of the biotechnology company’s stock worth $4,810,000 after acquiring an additional 620,242 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its stake in Viking Therapeutics by 124.4% in the 4th quarter. Renaissance Technologies LLC now owns 903,300 shares of the biotechnology company’s stock worth $3,667,000 after acquiring an additional 500,700 shares in the last quarter. 20.21% of the stock is owned by hedge funds and other institutional investors.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.